ANDA 214532, held by Chartwell Rx. Triamcinolone Acetonide.
As of Nov 15, 2026, ANDA 214532 (Triamcinolone Acetonide), held by Chartwell Rx, was first approved by FDA on Jan 27, 2023, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 27, 2023 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Triamcinolone Acetonide0.05% ยท ointment;topical | Triamcinolone Acetonide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
